Katrina Pollock
MA MBBS MRCP DipGUM DipHIV DFSRH PhD
MRC Clinician Scientist in Vaccinology
- Chief investigator for the Lymph nodE single-cell Genomics AnCestrY and ageing (LEGACY) Network
- Chief and principal investigator for experimental medicine and first-in-human vaccine studies
- Honorary consultant in sexual health.
Human tissue based vaccine immunology.
Biography
Dr Katrina Pollock is an MRC Clinician Scientist in Vaccinology at the Oxford Vaccine Group, University of Oxford, Honorary Clinical Senior Lecturer in Vaccinology at the Department of Infectious Disease, Imperial College London, and Honorary Consultant in Sexual Health. She read medicine as an undergraduate at Newnham College, University of Cambridge, and Imperial College London before completing specialty training as a clinician scientist in genitourinary and HIV medicine, with a PhD and lectureship in immunology. Having led a series of first-in-human trials of novel vaccines including COVID-19 at Imperial College London, she received an award for substantial and exceptional achievement during the COVID-19 pandemic. Her work seeks to define tissue-based mechanisms of vaccine immunogenicity in diverse populations to leverage this for novel vaccine design. She is passionate about involving the public and participants at all stages, to lead innovative research that changes lives for the better.
Recent publications
-
Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.
Journal article
Writing Committee for the REMAP-CAP Investigators None. et al, (2023), JAMA, 329, 1183 - 1196
-
COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2
Journal article
Szubert AJ. et al, (2023), eClinicalMedicine, 56
-
Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine.
Journal article
Liu Z. et al, (2023), Gastroenterology, 164, 300 - 303.e3
-
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Journal article
Liu Z. et al, (2023), Lancet Gastroenterol Hepatol, 8, 145 - 156
-
The effect of TRV027 on coagulation in COVID-19: A pilot randomized, placebo-controlled trial.
Journal article
Robbins AJ. et al, (2022), Br J Clin Pharmacol